The European Union gained another high-concentration adalimumab biosimilar with the approval of Sandoz’ Hyrimoz HCF and the FDA accepted a biologics license application for a trastuzumab biosimilar (HLX02).
The European Union gained another high-concentration adalimumab biosimilar with the approval of Sandoz’ Hyrimoz HCF and the FDA accepted a biologics license application for Accord BioPharma and Shanghai Henlius Biotech’s trastuzumab biosimilar (HLX02).
European Approval of Hyrimoz HCF
The European Commission has granted marketing authorization to Sandoz’ citrate-free, high-concentration (HCF) version of its adalimumab biosimilar, Hyrimoz. The HCF formulation allows for patients to receive treatment with a reduced injection volume (100 mg/mL vs 50 mg/mL) and less injection site pain compared with the original, low-concentration version.
Hyrimoz HCF will be used to treat patients with rheumatoid arthritis, Crohn disease, ulcerative colitis, plaque psoriasis, uveitis, and hidradenitis suppurativa. The biosimilar references Humira, one of the most profitable drugs in the world. The news comes after the FDA approved Hyrimoz HCF (adalimumab-adaz) in March 2023.
“Living with a chronic disease can take a significant toll on a patient’s quality of life. Biosimilars help patients to gain broader access to effective and high-quality treatments that improve their disease therapies,” said Rebecca Guntern, head of region Europe at Sandoz, in a statement.
The approval was based on a phase 1 pharmacokinetics (PK) bridging study comparing the low-concentration version of the biosimilar vs Hyrimoz HCF. The study met all the primary endpoints and demonstrated comparable PK, safety, and immunogenicity profiles between the 2 formulations.
“With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. Today’s approval brings Sandoz one step closer to providing European patients with chronic conditions an additional treatment option that offers increased convenience and a reduction in injection volume,” Guntern explained.
FDA Accepts BLA for HLX02
Accord BioPharma, the US division of Intas Pharmaceuticals, announced that the FDA has accepted its BLA for HLX02, a proposed trastuzumab biosimilar, for the treatment of human epidermal growth factor 2 (HER2)-overexpressing breast and gastric cancer.
The product references Herceptin (trastuzumab) and if approved, it will become the sixth trastuzumab biosimilar to receive regulatory approval in the United States.
“We're thrilled to announce this regulatory milestone as we work to provide patients increased options and access for treatment of serious conditions in oncology, immunology, and critical care,” commented Chrys Kokino, president of US BioPharma at Accord BioPharma.
HLX02 was originally developed by Accord BioPharma’s business partner Shanghai Henlius Biotech. As part of their agreement, in 2021, Henlius gave Accord the exclusive rights to develop and commercialize HLX02 in the United States and Canada.
The biosimilar has been approved in over 30 countries, including those in the European Union (July 2020) as well as China (August 2020) for the same indications as the originator product. The BLA submission included data from nonclinical studies; a phase 1 PK similarity study; and a global, multicentric phase 3 safety, efficacy, and immunogenicity study in relevant patient populations. The phase 3 analysis demonstrated biosimilarity between the biosimilar and the reference product.
Kokino added, “Biosimilars are key to making healthcare more affordable and accessible. We're working to develop the deepest portfolio of biosimilars to enhance the patient experience and improve the cost of care across the continuum.”
Accord BioPharma also has 2 other biosimilars that have been approved in the United States, and the company said that it plans to introduce more in the next 5 years.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.